News Focus
News Focus
Post# of 257268
Next 10
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 17445

Thursday, 10/27/2005 12:12:01 PM

Thursday, October 27, 2005 12:12:01 PM

Post# of 257268
Clinical-trial / regulatory calendar:

[Please see updating procedure at the end of this post.]


Edits: Added IMCL entry for PFS data in first-line CRYSTAL trial.
.

ABGX- pivotal Panitumumab results in third-line CRC: mid Nov.

AGEN - Ph III in RCC 1H06.

AGIX - 1H 06 - Ph iii of 1067 on MACE should hit 900+ events for the end of the trial.

ALKS – 12/30/05 PDUFA date for Vivitrex NDA.

AMGN – See ABGX

AORMF -pivotal AMD3100 results 2nd half 06.

AVN – FDA acceptance for filing of NDA for PBA: delayed (was 10/10/05).

AXCA -pivotal Itax results 1st half 06.

BMY – 12/31/05 revised action date for Orencia (CTLA-4).

BOMSF -reporting pivotal MBP8298 results 2 years roughly

CEPH – Nuvigil PDUFA date in EDS: 1/06; Oravescent Fentanyl PDUFA date: 7/6/06.

COR - Oct 2005: Interim analysis - IIa Alzheimer's CX-717 Ampakine trial.
COR - Approx Year end 2005: Results of IIa ADHD CX-717 Ampakine trial.
COR - Early 2006: Results of IIa Simulated Night Shift Work (Sleep Disorder) CX-717 Ampakine trial (funded by DARPA).

CORT - 1H 06 - Results of Ph iii of RU-486 on Psychotic MD

CRME - Phase III RSD1235 ACT 2 CABG data in Q4/05 or Q1/06

CYAHF -20 patient IDE results 4th qtr, then begin the pivotal phase 1st half 06 as well as commercial launch in Europe later this year.

CYPB – Phase-3 Milnacipran in fibromyalgia, second phase-3 study (either 3-mo or 6-mo of follow-up) 3Q06 (maybe —Dew).

DNA - Rituxan ph III results in RA in Q3 05
DNA - Lucentis phase-3 ANCHOR (predominantly-classic AMD) in 4Q05.

DNDN - 10/31/05 full survival data (and possibly less important ttp data as well) from Provenge 9902A trial to be presented at ECCO
DNDN - 1H 06 - Results for Ph iii of Provenge efficacy on PSADT in ADPC

FRX - Milnacipran in fibromyalgia: see CYPB.

GENR – Interim data in phase-2 “209” study: early 2006.

GPCB – Satraplatin SPARC trial: interim efficacy 1Q06, final efficacy 2Q06. (Endpoint is a complex TTP metric.)

GTCB – EMEA opinion on ATryn: Feb. 2006; Merrimack phase-2b MM-093 in RA: mid 2006.

IDBE -begin pivotal Fluinsure trials this winter.

IMCL – Erbitux PFS in (Merck KGaA) CRSYTAL trial in first-line CRC: 2H06; Erbitux H&N PDUFA date: end of Feb 06 (sBLA submitted 8/30/05).

INSM – Approvable letter received—orphan status pending.

ISTKF – 12-week Phase III ISA247 psoriasis results reported in August. 24-week results due in 4Q05.

LBPFF -report Tramadol Phase III U.S. results 2nd half as well as European launch 4th qtr.

Merrimack: see GTCB

MYOG - Top-line data from Ambrisentan phase-3 trials in PAH: ARIES-2 in 4Q05, ARIES-1 in 2Q06.

NABI - ph iii results for vaccine against staph in Q4 05

NKTR – Exubera endorsed by advisory panel 9/8/05 by 7-2 vote, awaiting FDA action.

NVS – LAF237 pivotal data in diabetes: early 2006.

PDLI - Q2 06 volociximab ph II for solid tumors

PTIE - All are 2H05
Oxytrex(TM) Osteoarthritic Pain - Phase III Report top-line results
PTI-901 Irritable Bowel Syndrome - P.III Report top-line results in women

PTN- Q2 2006 ph.IIb results for PTN-141 in male erectile dysfunction

SPPI – See GPCB.

SRDX - Phase-1 AMD data for I-vation w Triamcinilone: mid 2006; Novocell start of phase-1/2 trial in type-1 diabetes: imminent.

TELK - Telcyta 3rd line NSCLC and 3rd line Ovarian results 1H06

Therion (private) – PanVac phase-3 survival results in second-line pancreatic cancer: 1Q06; ProstVac phase-2 (TTP) results of 120-patient trial in asymptomatic HRPC: 1Q06; start of ProstVac phase-3, 600-patient NCI trial in HDPC: 1H06.

TH.TO -report ThGrf Phase III Hiv-associated lipodystrophy results late 06.

VSGN - Celacade phase-3 in chronic HF (ACCLAIM) fiscal 1Q06 (Dec 05-Feb 06).

YMI - early 2006?--672 patients enrolled, 28 to go.YM anticipated that the trial might be completed as early as mid-2006, but seems to be potentially ahead of schedule.
YMI - report pivotal Tesmilifine breast cancer results possibly 2nd qtr 06.
YMI – AeroLEF phase-2b data report: 2Q06.


--
Procedure For Updating Clinical-Trials List

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.

2. Make your additions or modifications, inserting any new items in alphabetical order.

3. Post the updated text in a new message in reply to the message with the old list.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today